Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Multiple Myeloma 14Lymphoma, Non-Hodgkin 10Breast Neoplasms 7Carcinoma, Non-Small-Cell Lung 6Lymphoma, Large B-Cell, Diffuse 5Lymphoma, B-Cell 5Lymphoma 5Solid Tumors 4Recurrence 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasms 4Melanoma 4Leukemia, Myeloid, Acute 4Leukemia, Lymphocytic, Chronic, B-Cell 4Arthritis, Rheumatoid 4Ovarian Neoplasms 3Lymphoma, Follicular 3Leukemia 3Hematologic Neoplasms 3Cytokine Release Syndrome 3Colorectal Neoplasms 3Burkitt Lymphoma 3Urinary Bladder Neoplasms 2Respiratory Distress Syndrome 2Pancreatic Neoplasms 2Myelodysplastic Syndromes 2Lymphoma, Mantle-Cell 2Fallopian Tube Neoplasms 2Craniopharyngioma 2Carcinoma, Hepatocellular 2

Interventions

Nutrition Assessment 3Transcranial Direct Current Stimulation 2urinastatin 1tocilizumab 1rimabotulinumtoxinB 1X-Rays 1Vitamin B 6 1Vitamin B 12 1Thrombectomy 1Standard of Care 1Saline Solution 1Rosuvastatin Calcium 1Resistance Training 1Practice Guidelines as Topic 1Phenylephrine 1Palliative Care 1Norepinephrine 1Music Therapy 1Massage 1Lysine Acetyltransferase 5 1Infliximab 1Immunoglobulin G 1Folic Acid 1Extracorporeal Shockwave Therapy 1Exergaming 1Enoxaparin 1Disulfides 1Dialectical Behavior Therapy 1Cholecalciferol 1Cerebral Angiography 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Stroke × tocilizumab × Clear all
NCT04361552 2020-06-18

Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)

Emory University

Phase 3 Withdrawn
Genitourinary

COVID-19, Coronary Artery Disease, Diabetes Mellitus, Kidney Failure, Chronic, Neoplasms, Stroke, Pulmonary Disease, Chronic Obstructive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡